Company: AZN
Filing Date: 2025-04-29
Form Type: 6-K
Source: 0001654954-25-004737
Chunk: 16

Company: ASTRAZENECA PLC
Filing Date: 2025-04-29
Form: 6-K
Chunk 16
---
                                  |      31 |    -674 |      705 |
| Interest paid                                                 |    -422 |    -341 |      -81 |
| Taxation paid                                                 |    -363 |    -430 |       67 |
| Net cash inflow from operating activities                     |   3,713 |   2,486 |    1,227 |
| Net cash inflow before financing activities                   |   2,460 |      73 |    2,387 |
| Net cash (outflow)/inflow from financing activities           |  -2,707 |   2,028 |   -4,735 |

Net cash flow

The change in Net cash inflow before financing activities of $2,387m is primarily driven by the reduction in cash outflow relating to the Acquisitions of subsidiaries, net of cash acquired of $726m, which in 2024 related to the acquisition of Gracell Biotechnologies Inc., and the reduction in cash outflow relating to Purchase of intangible assets which included an outflow of $639m relating to the acquisition of Icosavax in 2024.

The change in Net cash (outflow)/inflow from financing activities of $4,735m is primarily driven by the issue of new long-term loans of $4,976m in 2024, with no issuance in 2025.

Capital expenditure

Capital expenditure on tangible assets and Software-related intangible assets amounted to $493m in Q1 2025 (Q1 2024: $474m). The increase of capital expenditure in 2025 was driven by investment in several major manufacturing projects and continued investment in technology upgrades.

Net debt

Net debt increased by $1,497m in the three months to 31 March 2025 to $26,067m. Details of the committed undrawn bank facilities are disclosed within the going concern section of Note 1. Details of the Company's solicited credit ratings and further details on Net debt are disclosed in Note 2.

Net debt

Table 11: Net debt summary

|                                                    | At 31 Mar 2025 
             $m | At 31 Dec 2024 
             $m | At 31 Mar 2024 
             $m |
| Cash and cash equivalents                          |          5,230 |          5,488 |          7,841 |
| Other investments                                  |            165 |            166 |            180 |
|